Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition

Cancer Research

Volumn 61, Issue 9, 2001, Pages 3535-3540

  Cusack, James C ^a,b   Liu, Rong ^b   Houston, Michael ^b   Abendroth, Karin ^b   Elliott, Peter J ^c   Adams, Julian ^c   Baldwin, Albert S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BORONIC ACID DERIVATIVE; BORTEZOMIB; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; MULTIENZYME COMPLEXES; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035328584     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Molecular determinants of sensitivity to antitumor agents
2. Apoptosis and therapy
3. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2
4. Involvement of the CD95 (APO-I/FAS) receptor/ligand system in drug- induced apoptosis in leukemia cells
5. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
6. Apoptosis in cancer therapy: Crossing the threshold
7. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells
8. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells
9. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation
10. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
11. Rapid proteolysis of IκBα is necessary for activation of transcription factor NF-κB
12. Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB
13. The NF-κB and IκB proteins: New discoveries and insights
14. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
15. Recent advances in understanding proteasome function
16. Proteasome inhibitors: A novel class of potent and effective antitumor agents
17. Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity
18. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-I-piperidino]-carbonyloxycamptothecin (CPT-I1) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation
19. The rise and fall of apoptosis during multistage tumorigenesis: Down-modulation contributes to tumor progression from angiogenic progenitors
20. Apoptosis: Its role in the development of malignancies and its potential as a novel therapeutic target
21. p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage
22. An essential role for NF-κB in preventing TNF-αinduced cell death
23. Suppression of TNF-α-induced apoptosis by NF-κB
24. New insights into proteasome function: From archaebacteria to drug development
25. How proteolysis drives the cell cycle
26. Structure and functions of the 20S and 26S proteasomes
27. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
28. Inhibition of NF-κB activation in vitro and in vivo: Role of 26S proteasome
29. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin